Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata

NCT06012240 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06012240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06012240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Recruiting
Start date
October 11, 2023
Completion date
April 30, 2030
Enrollment
1,500 (estimated)
Sites
272

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata